Evidence map›Paper›PMID 19634987›Full record

ReviewAntioxidants & redox signaling2010

Redox control of asthma: molecular mechanisms and therapeutic opportunities.

Suzy A A Comhair, Serpil C Erzurum

Erratum issued 2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 125 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01221350 nacompletednot on this map

Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.

TypeinterventionalSponsorCentro Universitario de Ciencias de la Salud, MexicoRan2010 to 2012Enrolled55ConditionsAsthma, Allergic RhinitisArmsLipoic acid, Placebo
NCT03926741 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Methods to Identify and Treat Severe Asthma Patients Project 1: GSNOR Phenotyping and GSNO Challenge

TypeinterventionalSponsorJames ReynoldsRan2019 to 2024Enrolled48ConditionsAsthmaArmsGSNO Challenge
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 1 synthesis or guideline pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Prostaglandin FThe Journal of veterinary medical science · 2025
    Article
  7. Article
  8. Ferroptosis: Disease Associations and Therapeutic Target Exploration.Journal of molecular neuroscience : MN · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Understanding the impact of ER stress on lung physiology.Frontiers in cell and developmental biology · 2024
    Review
  19. Review
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Ghio,Andrew [removed]; Kinnula, Vuokko [removed]; Kliment, Corrine [removed];Montuschi, Paolo [removed]; Reddy, Sekhar [removed]; White, Carl [removed]
5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Suzy A A ComhairPathobiology, Lerner Research Institute, and the Respiratory Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. comhais@ccf.org
Serpil C Erzurum
Cleveland Clinic Lerner College of Medicine · US

Funding

Tissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ARONICA, MARK A · 2006 to 2019
$17.8M
Redox Determinants of Severe AsthmaR01HL069170 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ERZURUM, SERPIL C. · 2001 to 2010
$5.1M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
The Regulation and Role of Nitric Oxide in AsthmaR01HL070649 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2003 to 2007
$1.2M
NHLBI NIH HHS HL081064NHLBI NIH HHS HL69170NHLBI NIH HHS P01 HL081064NHLBI NIH HHS R01 HL069170NHLBI NIH HHS R01 HL070649NHLBI NIH HHS U10 HL109250NIAID NIH HHS AI70649
6 · The paper itself

Abstract

An imbalance in reducing and oxidizing (redox) systems favoring a more oxidative environment is present in asthma and linked to the pathophysiology of the defining symptoms and signs including airflow limitation, hyper-reactivity, and airway remodeling. High levels of hydrogen peroxide, nitric oxide ((*)NO), and 15-F(2t)-isoprostane in exhaled breath, and excessive oxidative protein products in lung epithelial lining fluid, peripheral blood, and urine provide abundant evidence for pathologic oxidizing processes in asthma. Parallel studies document loss of reducing potential by nonenzymatic and enzymatic antioxidants. The essential first line antioxidant enzymes superoxide dismutases (SOD) and catalase are reduced in asthma as compared to healthy individuals, with lowest levels in those patients with the most severe asthma. Loss of SOD and catalase activity is related to oxidative modifications of the enzymes, while other antioxidant gene polymorphisms are linked to susceptibility to develop asthma. Monitoring of exhaled (*)NO has entered clinical practice because it is useful to optimize asthma care, and a wide array of other biochemical oxidative and nitrative biomarkers are currently being evaluated for asthma monitoring and phenotyping. Novel therapeutic strategies that target correction of redox abnormalities show promise for the treatment of asthma.

Indexed as

AsthmaCatalaseHumansLungOxidation-ReductionReactive Nitrogen SpeciesReactive Oxygen SpeciesSuperoxide DismutaseCatalaseReactive Nitrogen SpeciesReactive Oxygen SpeciesSuperoxide Dismutase

Identifiers

PMID19634987
PMCPMC2824520
OpenAlexW2099716328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.